| Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy JL Carter, K Hege, J Yang, HA Kalpage, Y Su, H Edwards, M Hüttemann, ... Signal transduction and targeted therapy 5 (1), 1-29, 2020 | 148 | 2020 |
| Targeting mitochondrial respiration for the treatment of acute myeloid leukemia JL Carter, K Hege, HA Kalpage, H Edwards, M Hüttemann, JW Taub, ... Biochemical pharmacology 182, 114253, 2020 | 40 | 2020 |
| Cotargeting of mitochondrial complex I and Bcl-2 shows antileukemic activity against acute myeloid leukemia cells reliant on oxidative phosphorylation F Liu, HA Kalpage, D Wang, H Edwards, M Hüttemann, J Ma, Y Su, ... Cancers 12 (9), 2400, 2020 | 38 | 2020 |
| Three-dimensional alginate hydrogels for radiobiological and metabolic studies of cancer cells GH Read, N Miura, JL Carter, KT Kines, K Yamamoto, N Devasahayam, ... Colloids and Surfaces B: Biointerfaces 171, 197-204, 2018 | 17 | 2018 |
| Enhanced production of human influenza virus in PBS-12SF cells with a reduced interferon response M Carvajal-Yepes, KRB Sporer, JL Carter, CJ Colvin, PM Coussens Human Vaccines & Immunotherapeutics 11 (9), 2296-2304, 2015 | 13 | 2015 |
| Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia KH Hurrish, X Qiao, X Li, Y Su, J Carter, J Ma, HA Kalpage, M Hüttemann, ... Biochemical Pharmacology 205, 115283, 2022 | 10 | 2022 |
| Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms JL Carter, Y Su, X Qiao, J Zhao, G Wang, M Howard, H Edwards, X Bao, ... Biochemical Pharmacology 216, 115759, 2023 | 4 | 2023 |
| Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro KH Hurrish, Y Su, S Patel, CL Ramage, J Zhao, BR Temby, JL Carter, ... Biochemical Pharmacology 220, 115981, 2024 | 3 | 2024 |
| Curing childhood cancer the “Natural” Way: Nature as the source of chemotherapy agents ET Al-Antary, A Gupte, J Carter, M Kaafarani, M Howard, H Edwards, Y Ge, ... Biochemical Pharmacology 213, 115630, 2023 | 3 | 2023 |
| Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia S Wu, H Edwards, D Wang, S Liu, X Qiao, J Carter, Y Wang, JW Taub, ... Cells 11 (17), 2752, 2022 | 2 | 2022 |
| The imipridone ONC213 targets α-ketoglutarate dehydrogenase to induce mitochondrial stress and suppress oxidative phosphorylation in acute myeloid leukemia Y Su, JL Carter, X Li, Y Fukuda, A Gray, J Lynch, H Edwards, J Ma, ... Cancer Research, 2024 | 1 | 2024 |
| A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis KH Hurrish, Y Su, S Wiley, Z Hou, J Carter, H Kalpage, M Hüttemann, ... Blood 138, 2238, 2021 | 1 | 2021 |
| Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis KH Hurrish, Y Su, S Patel, CL Ramage, JL Carter, H Edwards, SA Buck, ... Research Square, 2023 | | 2023 |
| ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and … KH Hurrish, Y Su, S Patel, SE Wiley, Z Hou, J Carter, H Kalpage, ... Cancer Research 82 (12_Supplement), 3785-3785, 2022 | | 2022 |
| Alginate hydrogels for three-dimensional culture and real-time monitoring of cancer cell metabolism and radiation response AH Kesarwala, JL Carter, GH Read, N Miura, K Yamamoto, JB Mitchell, ... International Journal of Radiation Oncology, Biology, Physics 99 (2), S148, 2017 | | 2017 |
